Drugs / COL7A1 gene-modified autologous fibroblasts
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02493816 | Sep 2015 → Mar 2018 | recessive dystrophic epidermolysis bullosa | King's College London | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COL7A1 gene-modified autologous fibroblasts | “3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.” NCT02493816 ↗ |
| Route | Other | “3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.” NCT02493816 ↗ |